The TLV places substantial weight on both the cost effectiveness and the severity of disease in reimbursement decisions, and the implied willingness to pay for a QALY is higher than the often cited 'rule of thumb' in Swedish policy debates.
All the estimated ICER values were higher than the thresholds usually described in the literature (€ 20,000-30,000/QALY), with relevant differences among the groups. In both scenarios, payers were less prone to pay for therapeutic improvements compared to the rest of the participants. On the other hand, oncologists were the ones that most valued gains in survival for a new treatment while patients assigned a higher value for money to a treatment that enhanced the quality of life. QA4 ReimbuRsement Decisions foR PhARmAceuticAls in sweDen: the imPAct of cost-effectiveness AnD DiseAse seveRity
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.